Biotia announced that it has published a clinical validation study in the Journal of the American Society for Microbiology. microbiology spectrum. This study validates next-generation sequencing (NGS) and machine learning-based approaches for detecting genitourinary pathogens and profiling antimicrobial resistance directly from clinical urine specimens.
Urinary tract infections (UTIs) are often difficult to diagnose using standard culture-based methods, especially when recurrent or complex. Biotia’s assays are designed to address these limitations by enabling culture-independent, “comprehensive” detection of bacteria and fungi, including those often missed by traditional diagnostic methods.
Clinical verification and track record
The study evaluated 1,470 clinical specimens across more than 1,600 reactions and achieved a sensitivity of 97.2% and specificity of 99.6%. The company’s proprietary machine learning classifier, BIOTIA-DX, supported this result by reducing false positives through the removal of contamination and commensal microorganisms.
antibacterial resistance Genetic profiling provided additional insights to guide targeted therapy, and built-in quality control was used to ensure consistent results.
“Combining clinical metagenomic sequencing and machine learning allows us to reliably detect a broader range of pathogens and support more precise, data-driven treatments,” Mara Couto-Rodriguez, Biotia’s chief scientific officer, said in the release. “These findings highlight the potential of NGS-based diagnostics to advance UTI care, reduce diagnostic uncertainty, and support antimicrobial stewardship.”
Evolving UTI diagnosis
The BIOTIA-ID urine test is approved by New York State as a laboratory-developed test. This validation study shows that the test provides the accuracy clinicians need to make informed treatment decisions for patients with recurrent or complicated UTIs that are often misdiagnosed by traditional methods.
“This publication highlights the growing role of clinical metagenomic sequencing in complex infectious disease cases. Biotia’s platform enables clinicians to move beyond the limitations of culture-based testing and toward a more comprehensive understanding of infectious diseases,” Dorottya Nagy-Szakal, MD, Biotia’s chief medical officer, said in the release.
The BIOTIA-ID urine test is now available to clinicians and patients.
ID 12418559 © Maria Ingstorp | Dreamstime.com
